La cadena de opciones muestra datos clave de las opciones de acciones de Conduit Pharmaceuticals a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Conduit Pharmaceuticals..

Conduit Pharmaceuticals (NASDAQ:CDT) Bolsa, Cadena de Opciones

Conduit Pharmaceuticals

Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being, prioritized by leading biopharmaceutical companies in order to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready in autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

Conduit Pharmaceuticals Inc. - Common Stock

Conduit Pharmaceuticals Inc

Infinitii Ai Inc

CDT Environmental Technology Investment Holdings Limited - ordinary shares

CDT Environmental Technology Investment Holdings Ltd

CDTI ADVANCED MATERIALS by CDTI Advanced Materials, Inc.

CDTi Advanced Materials Inc

Cidara Therapeutics Inc

Needham analyst James Ricchiuti reiterates 3D Sys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DDD#NYSE">DDD</a>) with a Hold.

News

Reiteration

Analyst Ratings

Needham Reiterates Hold on 3D Sys

Aegon trading update for third quarter 2024&nbsp;
• EUR 336 million operating capital generation, before holding funding and operating expenses. Full-year 2024 guidance raised to around EUR 1.2 billion, from around EUR 1.1 billion previously&nbsp;
• Capital ratios of the main units remain above their respective operating levels&nbsp;
• Planned new EUR 150 million share buyback program announced; completion expected in the first half of 2025. The program includes neutralization of shares issued for share-based compensation plans&nbsp;
• Cash Capital at Holding of EUR 1.5 billion as of September 30, 2024. Expect to reach mid-point of the target range (EUR 1.0 billion) by the end of 2026&nbsp;
• Completed program to purchase institutionally owned universal life policies. Terminated policies negatively impacted US RBC ratio by 16%-points. Expect 8%-points benefit in 4Q 2024 after equity funding repayment. Operating capital generation benefits from the program, as previously guided&nbsp;
• Strong commercial momentum in Asset Management and UK Workplace platform. US Strategic Assets experience c

Aegon Q3 Business Update: Operating Capital Generation €336M Before Holding Expenses; Raised FY24 Operating Capital Target To ~€1.2B, Up From The Previous Estimate Of €1.1B

HC Wainwright &amp; Co. analyst Vernon Bernardino reiterates Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) with a Buy and maintains $8 price target.

Price Target

GOVX

HC Wainwright & Co. Reiterates Buy on Geovax Labs, Maintains $8 Price Target

HC Wainwright &amp; Co. analyst Emily Bodnar reiterates MiNK Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INKT#NASDAQ">INKT</a>) with a Buy and maintains $9 price target.

INKT

HC Wainwright & Co. Reiterates Buy on MiNK Therapeutics, Maintains $9 Price Target

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Shattuck Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STTK#NASDAQ">STTK</a>) with a Neutral.

STTK

HC Wainwright & Co. Reiterates Neutral on Shattuck Labs

Macro Economic Events

Econ #s

Economics

U.K. Labour Productivity For Q2 0.2% Vs. 0.1% Prior

HC Wainwright &amp; Co. analyst Yi Chen reiterates Orchestra BioMed Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OBIO#NASDAQ">OBIO</a>) with a Buy and maintains $14 price target.

Orchestra BioMed Holdings, Inc. - Ordinary Shares

OBIO

HC Wainwright & Co. Reiterates Buy on Orchestra BioMed Hldgs, Maintains $14 Price Target

Coca-Cola European Partners plc Ordinary Shares

CCEP

Coca-cola Europacific Partners Says The Financial Conduct Authority Approved Its Transfer Of Listing Category From Equity Shares Category To Equity Shares (Commercial Companies) Category Of Official List

Michael Burry, the hedge fund manager renowned for predicting the 2008 financial crisis, has significantly increased his exposure to Chinese technology companies while simultaneously implementing protective measures against potential downside risks, <a href="https://www.benzinga.com/markets/asia/24/11/42000692/david-teppers-appaloosa-trims-alibaba-stake-by-476-in-q3-2024-doubles-down-on-pdd-holdings-and-jd.com">according to regulatory filings</a>.
What Happened: Burry&#8217;s Scion Asset Management made several notable adjustments to its portfolio during the third quarter, with Chinese companies now representing its largest positions. The firm increased its stake in Alibaba Group Holding Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) by 29%, making it the fund&#8217;s largest holding valued at over $21 million as of September&#8217;s end.
In a similar move, Scion doubled its position in JD.Com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>), elevating it to the fund&#8217;s second-largest holding at approximately $20 million. The firm also expanded its stake in Chinese search giant Baidu Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) by 67%, bringing the position to $13.2 million.
However, in what appears to be a cautionary strategy, Burry has simultaneously established put options against these same holdings. Put options typically increase in value when the underlying securities decline, suggesting a hedging strategy designed to protect against potential market volatility.
See Also: <a href="https://www.benzinga.com/news/global/24/11/41999238/ross-gerber-blasts-teslas-support-for-ending-ev-tax-credit-as-insanity-amid-reported-policy-shift-under-trump-administration">Long-Time Tesla Bull Rages As Elon Musk Reportedly Backs Trump&#8217;s Plan To Ax $7.5K EV Credit: &#8216;Insanity&#8217;</a>
The timing of these moves coincides with Beijing&#8217;s recent economic stimulus announcements aimed at reinvigorating growth in the world&#8217;s second-largest economy. While Chinese equities initially rallied in September following these signals, gains have moderated as investors await more concrete fiscal measures.
Beyond his Chinese technology focus, Burry has also increased positions in several U.S. companies, including Shift4 Payments Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOUR#NYSE">FOUR</a>), American Coastal Insurance Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACIC#NASDAQ">ACIC</a>), and Molina Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>).
Why It Matters: Burry&#8217;s <a href="https://www.benzinga.com/markets/equities/24/10/41248334/big-short-investor-michael-burrys-china-bet-pays-off-as-top-picks-surge-nearly-60-in-2-months">top three Chinese holdings</a> have posted average gains of nearly 60% over a two-month period, according to market data.
Burry&#8217;s moves are being closely watched by market participants, particularly given his track record. He gained widespread recognition for his prescient bet against mortgage-backed securities before the 2008 global financial crisis, a story later chronicled in Michael Lewis&#8216;s bestseller &#8220;The Big Short&#8221; and its subsequent Oscar-winning film adaptation.
It&#8217;s worth noting that these positions reflect holdings as of Sep. 30, as required by SEC regulations for funds managing over $100 million in assets. Given the 45-day reporting delay and Burry&#8217;s active trading style, current positions may have already changed.
The development comes as other <a href="https://www.benzinga.com/markets/asia/24/11/42000692/david-teppers-appaloosa-trims-alibaba-stake-by-476-in-q3-2024-doubles-down-on-pdd-holdings-and-jd.com">prominent investors adjust their Chinese holdings</a>. Billionaire investor David Tepper&#8217;s Appaloosa Management recently reduced its Alibaba stake by 5%, though the position remains the fund&#8217;s largest holding at 15.75% of its $6.7 billion portfolio.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/content/41999311/jim-cramer-says-these-10-frothy-stocks-are-up-over-200-ytd-including-rocket-lab-palantir-and-carvana">Jim Cramer Says These 10 &#8216;Frothy&#8217; Stocks Are Up Over 200% YTD, Including Rocket Lab, Palantir, And Carvana</a></li>
</ul>
Image Via Shutterstock 
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Equities

Global

Markets

ACIC

BABA

BIDU

FOUR

'Big Short' Investor Michael Burry Doubles Down On Chinese Tech Stocks While Adding Protective Hedges

NATL

NCR Atleos Inks Five-year Agreement To Provide Atleos' Cashzone Network ATMs In The John Lewis Partnership's Waitrose Supermarkets Across The UK

Earnings

RLX Technology Q3 Adj EPADS $0.03, Sales $107.77M Beat $105.08M Estimate

Benchmark analyst Cody Acree maintains Tower Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSEM#NASDAQ">TSEM</a>) with a Buy and raises the price target from $55 to $60.

TSEM

Benchmark Maintains Buy on Tower Semiconductor, Raises Price Target to $60

Shares of Domino&#8217;s Pizza, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NYSE">DPZ</a>) rose sharply in today's pre-market trading after a 13F filing showed that Berkshire Hathaway <a href="https://www.benzinga.com/markets/equities/24/11/41993666/warren-buffetts-berkshire-hathaway-slashes-apple-bofa-holdings-adds-dominos-pizza-in-q3">added a new stake</a>.
Buffett bought 1,277,256 shares of Ann Arbor, Michigan-based pizza chain Domino's Pizza.
Domino&#8217;s Pizza shares jumped 7.8% to $470.00 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>The Arena Group Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AREN#NYSE">AREN</a>) gained 233.3% to $1.90 in pre-market trading after it announced its first ever profitable quarter.</li>
<li>Greenidge Generation Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GREE#NASDAQ">GREE</a>) rose 49.8% to $3.70 in pre-market trading. Greenidge said New York Supreme Court Judge rejected Department of Environmental Conservation&#8217;s action to deny its application for renewal of Title V Air Permit.</li>
<li>Innovation Beverage Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBG#NASDAQ">IBG</a>) gained 35.2% to $1.46 in pre-market trading after gaining 40% on Thursday.</li>
<li>Beneficient (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BENF#NASDAQ">BENF</a>) gained 29.6% to $1.62 in pre-market trading after the company reported a year-over-year increase in second-quarter revenue results.</li>
<li>Siyata Mobile Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYTA#NASDAQ">SYTA</a>) gained 26.6% to $1.62 in pre-market trading following third-quarter results.</li>
<li>TCTM Kids IT Education Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCTM#NASDAQ">TCTM</a>) gained 23.1% to $0.99 in pre-market trading after dipping 12% on Thursday.</li>
<li>Red Cat Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCAT#NASDAQ">RCAT</a>) climbed 19.4% to $4.80 in pre-market trading after jumping more than 5% on Thursday.</li>
<li>Despegar.com, Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DESP#NYSE">DESP</a>) gained 12.8% to $16.77 in pre-market trading after the company reported better-than-expected third-quarter financial results.</li>
<li>Jet.AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JTAI#NASDAQ">JTAI</a>) gained 9.8% to $6.37 in pre-market trading after dipping more than 28% on Thursday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>TFF Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TFFP#NASDAQ">TFFP</a>) shares tumbled 69.7% to $0.4890 in pre-market trading after the company announced it will wind down its operations.</li>
<li>Quantum Computing Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) shares fell 25.5% to $3.28 in pre-market trading after the company reported a registered direct offering of $40 million priced at-the-market under Nasdaq rules.</li>
<li>Expion360 Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XPON#NASDAQ">XPON</a>) shares fell 22.3% to $2.68 in pre-market trading after the company reported a year-over-year decline in third-quarter revenue results.</li>
<li>Digital Brands Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBGI#NASDAQ">DBGI</a>) declined 21.8% to $0.1060 in pre-market trading after the company reported worse-than-expected third-quarter EPS results and a year-over-year decline in revenue.</li>
<li>Tivic Health Systems Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) dipped 15.9% to $0.31 in pre-market trading after the company reported a year-over-year decline in third-quarter sales results.</li>
<li>CERo Therapeutics Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) shares dipped 14.7% to $0.16 in pre-market trading after falling around 12% on Thursday.</li>
<li>AST SpaceMobile, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) fell 13.8% to $23.10 in pre-market trading after the company reported worse-than-expected quarterly financial results.</li>
<li>Carmell Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTCX#NASDAQ">CTCX</a>) fell 13.1% to $0.24 in pre-market trading after posting third-quarter results.</li>
<li>Oklo Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>) fell 7.8% to $22.00 in pre-market trading following third-quarter results.</li>
<li>Applied Materials, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) fell 7.3% to $172.55 in today's pre-market trading following first-quarter results.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41971544/jim-cramer-recommends-microsoft-praises-american-water-works-for-being-consistent">Jim Cramer Recommends Microsoft, Praises American Water Works For Being &#8216;Consistent&#8217;</a></li>
</ul>

Pre-Market Outlook

Movers

Trading Ideas

AMAT

AREN

ASTS

BENF

CERO

CTCX

DBGI

DESP

GREE

JTAI

OKLO

QUBT

RCAT

SYTA

TCTM

TFFP

TIVC

XPON

Why Domino's Pizza Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket

Needham analyst Quinn Bolton reiterates D-Wave Quantum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>) with a Buy and maintains $2.25 price target.

QBTS

Needham Reiterates Buy on D-Wave Quantum, Maintains $2.25 Price Target

Needham analyst Joseph Stringer reiterates Annexon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANNX#NASDAQ">ANNX</a>) with a Buy and maintains $16 price target.

ANNX

Needham Reiterates Buy on Annexon, Maintains $16 Price Target

Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and Apple Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) key suppliers — Hon Hai Precision Industry Co. Ltd. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/HNHPF#OTC">HNHPF</a>), popularly known as Foxconn, Pegatron Corp. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/PGTRF#OTC">PGTRF</a>), and Quanta Computer (OTC:<a class="ticker" href="https://www.benzinga.com/stock/QUCCF#OTC">QUCCF</a>) — plan to quickly increase U.S. investments <a href="https://www.benzinga.com/markets/24/11/41869001/heres-how-trumps-policies-might-shape-the-markets-future">should trade policies shift</a> under Donald Trump&#8217;s second term.
What Happened: Foxconn chairman Young Liu announced on Thursday that the company is ready to expand its U.S. operations. The company is a leading contract electronics manufacturer and has substantial production bases in Texas, Wisconsin, and Ohio.
&#8220;We can very quickly adjust&nbsp;our investment if necessary,&#8221; Liu said at an investor&#8217;s conference, <a href="https://asia.nikkei.com/Spotlight/Supply-Chain/Nvidia-and-Apple-suppliers-ready-to-boost-U.S.-investments-under-Trump">reported</a> Nikkei Asia.
Pegatron, a key supplier to Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), and Apple, is also prepared to respond swiftly to any policy changes.
&#8220;If necessary, we can quickly convert [our repair facility in Indiana] into production lines to accommodate policy changes [such as tariffs],&#8221; co-CEO Johnson Deng told investors, according to the report.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41927379/elon-musk-says-the-prophecy-has-been-fulfilled-peanut-the-squirrel-themed-meme-coin-spikes-11?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk Says The &#8216;Prophecy Has Been Fulfilled&#8217; — Peanut The Squirrel-Themed Meme Coin Spikes 11%</a>
Quanta Computer&#8217;s cloud-computing subsidiary, QCT, is ready to expand its manufacturing capacity in California if needed, said the company&#8217;s president, Mike Yang.
&#8220;We have continued to expand our capacity there in the past two years and have space to further expand anytime if needed. We also have a footprint in Thailand as well.&#8221;
Why It Matters: During his campaign, Trump underscored his &#8220;America First&#8221; agenda and warned of <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41953220/dollar-powers-to-4-month-highs-against-yen-trump-tariff-expectations-spark-carry-trade-frenzy">potential tariffs on various countries</a>, creating uncertainty for the tech supply chain.
Despite these political uncertainties, Foxconn and other leading tech suppliers continue to view artificial intelligence as the key growth driver for the industry through 2025, the report noted.
The stock market and cryptocurrency sector have seen <a href="https://www.benzinga.com/general/social-media/24/11/41912771/trump-presidency-magnificent-7-stock-impact-benzinga-readers-pick-tech-titan-at-most-risk-following-2024-election">significant growth since Trump&#8217;s victory</a>, with major U.S. stock indexes hitting record highs since Trump&#8217;s win against Vice President Kamala Harris.
Earlier this week, Yang Chin-long, the governor of Taiwan's central bank, <a href="https://www.benzinga.com/news/global/24/11/41972365/tsmcs-65b-investment-in-us-will-help-avoid-trade-imbalance-says-taiwan-central-bank-governor-as-trump-returns-to-white-house">voiced optimism about</a> Taiwan Semiconductor Manufacturing Co.'s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) upcoming $65 billion investment in U.S. factories.
&#8220;Chips and information and telecommunications products are what the U.S. needs most. I don't think the United States would penalize Taiwan,&#8221; he said during a legislative session on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41931993/dogecoin-tumbles-despite-elon-musk-vivek-ramaswamys-doge-appointment-this-is-what-indicators-tell-about-its-next-moves?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Dogecoin Tumbles Despite Elon Musk, Vivek Ramaswamy&#8217;s &#8216;DOGE&#8217; Appointment: This Is What Indicators Tell About Its Next Moves</a></li>
</ul>
Disclaimer: This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Tech

Media

AAPL

HNHPF

MSFT

NVDA

PGTRF

QUCCF

TSLA

Nvidia, Apple Suppliers Brace For Trump's Return: Foxconn, Pegatron, Quanta Prepare For Rapid US Investment Boom

Chinese retail sales grew by 4.8% year-on-year in October picking up from September&#8217;s 3.2% growth, as per the National Bureau of Statistics on Friday. That annual retail sales forecast exceeded the 3.8% growth precited by a Reuters poll.
What Happened: The robust growth in Chinese retail sales in October was fueled by the monetary stimulus measures that the People's Bank of China unveiled in the latter half of September as a last-ditch effort to revive the country's struggling economy.
The share price of the top three Chinese e-commerce players, Alibaba Group Holding Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>), PDD Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>) and JD.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) were in red in Hong Kong on Friday.
Meanwhile, Alibaba Group Holding&#8216;s American Depository Receipts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) have plunged by 11.90% over the last month, according to <a href="http://pro.benzinga.com">Benzinga Pro data</a>. PDD Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>) and JD.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) ADRs have declined by 13.10% and 18.93%, respectively. The shares have underperformed their index, as the NYSE Composite rose by 0.28%, while the Nasdaq Composite advanced by 4.32% in the same period.
Also read: <a href="https://www.benzinga.com/general/market-summary/24/11/41968003/gold-drops-to-a-two-month-low-as-investors-turn-to-bitcoin-after-trumps-victory-but-this-economist-remains-confident-that-gold-will-surge">Gold Drops To A Two-Month Low As Investors Turn To Bitcoin After Trump&#8217;s Victory, But This Economist Remains Confident That &#8216;Gold Will Surge&#8217;</a>
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="252" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15032756/chinese-stocks-1-month-1024x252.png" alt="" class="wp-image-649725" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15032756/chinese-stocks-1-month-1024x252.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15032756/chinese-stocks-1-month-300x74.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15032756/chinese-stocks-1-month-768x189.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15032756/chinese-stocks-1-month-1536x377.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15032756/chinese-stocks-1-month.png 1738w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Why It Matters: The <a href="https://www.benzinga.com/government/regulations/24/11/41843262/chinas-stimulus-plan-not-enough-to-ignite-stocks#:~:text=The%20new%20stimulus%20plan%2C%20confirmed,to%20local%20authorities%2C%20CNBC%20reports.&amp;text=Additionally%2C%20central%20authorities%20will%20issue,over%20the%20next%20five%20years.">Chinese stimulus is aimed at stimulating</a> spending and investment in an economy that's been suffering from weak demand and a cooling property market. The measures also include a stimulus package of around 1 trillion yuan, or more than $140 billion, in liquidity.
Read next: <a href="https://www.benzinga.com/news/earnings/earnings-beats/24/11/41964200/apples-key-supplier-foxconns-gross-profit-hit-7-year-high-in-q3-aims-to-expand-ai-capabilities-by-next-year">Apple&#8217;s Key Supplier Foxconn&#8217;s Gross Profit Hit 7 Year High In Q3, Aims To Expand AI Capabilities By Next Year</a>
Image via Shutterstock

Citigourp Global Markets 2% Protected Notes Linked To The Djia

Chinese Retail Sales Pickup In October: Here's What's Happening With Alibaba, JD And Pinduoduo Shares

Piper Sandler analyst Arvind Ramnani reiterates Mastercard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) with a Overweight and raises the price target from $565 to $575.

Piper Sandler Reiterates Overweight on Mastercard, Raises Price Target to $575

Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) is offering three months of free full self-driving (FSD) subscription and supercharging for customers who take delivery of a new inventory vehicle till the end of the year in North America in a bid to increase annual deliveries.
What Happened: Customers who take delivery of new inventory vehicles between Nov. 14 and Dec. 31 are eligible for the offer. The offer extends to Tesla&#8217;s entire lineup, including its latest offering- the Cybertruck.
Tesla recently added the Cybertruck to its inventory. Until then, potential customers had to customize their vehicles and await delivery instead of picking one from inventory. 
The offer comes amidst Tesla&#8217;s efforts to boost its fourth-quarter delivery numbers. The company is also offering discounts on <a href="https://www.benzinga.com/news/24/10/41443856/tesla-offers-discounts-of-up-to-4k-on-select-model-3-y-vehicles-as-it-looks-to-avert-1st-ever-declin">some inventory vehicles in the U.S. </a>and offers in other offers in geographies <a href="https://www.benzinga.com/tech/24/11/41892379/tesla-offers-a-year-of-supercharging-for-free-in-europe-as-it-chases-record-q4-deliveries-to-outpace-a-slowdown">including Europe.</a> 
Why It Matters:&nbsp;For the full year 2023, Tesla delivered 1,808,581 vehicles around the globe. To mark a growth over last year, the company has to deliver at least 514,926 vehicles in the three months through the end of December. Tesla has never managed to deliver over 500,000 EVs in a quarter to date, making this an <a href="https://www.benzinga.com/tech/24/11/41894615/tesla-q4-deliveries-expected-to-set-new-records-but-not-enough-to-avoid-yearly-sales-decline-says-researcher">ambitious target.</a>
In the third quarter, Tesla reported deliveries of 462,890 vehicles, up 6.4% year-over-year and up 4.3% quarter-over-quarter.
Deliveries fell 8.5% year-on-year in the first quarter and by 4.8% in the second quarter.
Price Action: Tesla shares declined 5.8% on Thursday to $311.18, and were down by 1.9% in premarket trading on Friday. Year-to-date, the Tesla stock has risen by 25.3%, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>.
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/partner/fintech/24/11/41939694/the-power-of-leverage-global-broker-octa-lays-out-the-ins-and-outs-of-this-trading-tool-for-trade" target="_blank" rel="noreferrer noopener">Ford Cuts Capri, Explorer EV Output Due To ‘Significantly Lower Than Expected Demand' After Pausing F-150 Lightning Production</a></li>
</ul>
Photo courtesy: Tesla

Tesla Offers 3 Months Of Free Supercharging, FSD Subscription For North American Buyers Till Year-End To Boost Deliveries

Reported Earlier, Bloom Energy Announces 1 GW Fuel Cell Deal With AEP, Providing Clean Power For AI Data Centers

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Greenpro Capital&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/grnq-stock-quote/">GRNQ</a>) stock is dropping on Tuesday after the financial consulting and corporate advisory services company&rsquo;s shares underwent a large rally during the prior day of trading.



This saw shares of GRNQ stock close out normal trading hours on Monday up more than 34%. That came with heavy trading as over 10 million units moved yesterday. To put that number in perspective, the daily average trading volume for Greenpro Capital shares is around 183,000.



This rally didn&rsquo;t come without any news. The catalyst behind it was Greenpro Capital announcing a new strategic partnership. This brings together Greenpro Capital, its subsidiary Green-X and Bank Islam Trust Company.



Greenpro Capital CEO Dr. CK Lee <a href="https://www.nasdaq.com/press-release/greenpro-capital-corp-and-green-x-corp-forms-strategic-alliance-bank-islam-trust">said this about the strategic alliance</a>.




&ldquo;We are extremely excited to have&nbsp;Bank Islam Trust&nbsp;as our strategic partner to penetrate the Muslim and&nbsp;Middle East&nbsp;communities. There is a huge demand for digital asset investments from the&nbsp;Middle East, and we will structure our STO and RWA assets as alternative investment products to cater to their demand.&rdquo;




<h2>GRNQ Stock Movement Today</h2>



Considering the rally yesterday, it makes sense that GRNQ stock would give up some of those gains today. That has the stock falling 19.1% as of Tuesday morning. Traders will note that GRNQ shares were down 5.6% year-to-date when markets closed yesterday.



Today&rsquo;s stock market movement comes with some 230,000 shares of GRNQ on the move. That&rsquo;s already above Greenpro Capital&rsquo;s daily average trading volume.



Investors will want to keep reading for more of the biggest stock market stories on Tuesday!



We have all of the hottest stock market happenings to report on today! That includes the latest news for Autonomix Medical&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/amix-stock-quote/">AMIX</a>) stock, Conduit Pharmaceuticals&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/cdt-stock-quote/">CDT</a>) stock and Silo Pharma&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/silo-stock-quote/">SILO</a>) stock this morning. All of this info is ready to go at the links below!



<h2>More Stock Market News for Tuesday</h2>



<ul><li><a href="https://investorplace.com/2024/07/why-is-autonomix-medical-amix-stock-down-17-today/">Why Is Autonomix Medical (AMIX) Stock Down 17% Today?</a></li>



<li><a href="https://investorplace.com/2024/07/why-is-conduit-pharmaceuticals-cdt-stock-up-73-today/">Why Is Conduit Pharmaceuticals (CDT) Stock Up 73% Today?</a></li>



<li><a href="https://investorplace.com/2024/07/why-is-silo-pharma-silo-stock-up-123-today/">Why Is Silo Pharma (SILO) Stock Up 123% Today?</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/07/why-is-greenpro-capital-grnq-stock-down-19-today/">Why Is Greenpro Capital (GRNQ) Stock Down 19% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Greenpro Capital (GRNQ) Stock Down 19% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to dive into the biggest pre-market stock movers on Thursday morning with all of the latest news this morning!



Moving stocks on Thursday are loads of earnings reports, a public stock pricing, and exclusive license deal and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Conduit Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/cdt-stock-quote/">CDT</a>) stock is rocketing more than 68% after announcing an <a href="https://www.nasdaq.com/press-release/conduit-pharmaceuticals-enters-exclusive-license-agreement-astrazeneca-multiple">exclusive license agreement</a>.</li>



<li>Anew Medical (NASDAQ:<a href="https://investorplace.com/stock-quotes/wena-stock-quote/">WENA</a>) shares are soaring over 49% alongside heavy pre-market trading.</li>



<li>Harrow (NASDAQ:<a href="https://investorplace.com/stock-quotes/hrow-stock-quote/">HROW</a>) stock is surging more than 39% with its <a href="https://finance.yahoo.com/news/harrow-announces-second-quarter-2024-200100329.html">latest earnings report</a>.</li>



<li>1847 Holdings (NYSEMKT:<a href="https://investorplace.com/stock-quotes/efsh-stock-quote/">EFSH</a>) shares are rising over 30% despite a lack of news this morning.</li>



<li>LuxUrban Hotels (NASDAQ:<a href="https://investorplace.com/stock-quotes/luxh-stock-quote/">LUXH</a>) stock is increasing more than 26% without any clear news today.</li>



<li>Coeptis Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/coep-stock-quote/">COEP</a>) shares are climbing over 24% on Thursday morning.</li>



<li>Aspen Aerogels (NYSE:<a href="https://investorplace.com/stock-quotes/aspn-stock-quote/">ASPN</a>) stock is heading close to 23% higher <a href="https://www.tipranks.com/news/company-announcements/aspen-aerogels-projects-financial-outlook-for-2024-2">with its new guidance</a>.</li>



<li>CompoSecure (NASDAQ:<a href="https://investorplace.com/stock-quotes/cmpo-stock-quote/">CMPO</a>) shares are gaining more than 19% on <a href="https://au.finance.yahoo.com/news/composecure-inc-cmpo-q2-earnings-233506766.html">Q2 earnings and revenue beats</a>.</li>



<li>Digital Turbine (NASDAQ:<a href="https://investorplace.com/stock-quotes/apps-stock-quote/">APPS</a>) stock is jumping over 18% with its <a href="https://www.prnewswire.com/news-releases/digital-turbine-reports-fiscal-2025-first-quarter-financial-results-302217006.html">most recent earnings report</a>.</li>



<li>Klaviyo (NYSE:<a href="https://investorplace.com/stock-quotes/kvyo-stock-quote/">KVYO</a>) shares are up more than 18% <a href="https://www.businesswire.com/news/home/20240807687579/en/Klaviyo-Announces-Second-Quarter-2024-Financial-Results">after a guidance increase</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Cardlytics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cdlx-stock-quote/">CDLX</a>) stock is crashing over 54% with its <a href="https://www.nasdaq.com/press-release/cardlytics-announces-second-quarter-2024-financial-results-2024-08-07">earnings report and a CEO change</a>.</li>



<li>Outset Medical (NASDAQ:<a href="https://investorplace.com/stock-quotes/om-stock-quote/">OM</a>) shares are plummeting more than 47% after <a href="https://finance.yahoo.com/news/outset-medical-inc-om-reports-223509136.html">missing Q2 revenue estimates</a>.</li>



<li>Bumble (NASDAQ:<a href="https://investorplace.com/stock-quotes/bmbl-stock-quote/">BMBL</a>) stock is diving over 40% after <a href="https://www.reuters.com/technology/bumble-dives-revenue-forecast-cut-triggers-worries-over-turnaround-2024-08-08/">cutting its revenue guidance</a>.</li>



<li>Viracta Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/virx-stock-quote/">VIRX</a>) shares are tumbling nearly 39% without any obvious news today.</li>



<li>Greenlane (NASDAQ:<a href="https://investorplace.com/stock-quotes/gnln-stock-quote/">GNLN</a>) stock is taking a more than 36% beating <a href="https://www.nasdaq.com/press-release/greenlanes-vaporcom-named-usa-todays-list-americas-top-online-retail-shops-recent">following a recent rally</a>.</li>



<li>JFrog (NASDAQ:<a href="https://investorplace.com/stock-quotes/frog-stock-quote/">FROG</a>) shares are sliding over 26% on <a href="https://finance.yahoo.com/news/jfrog-nasdaq-frog-misses-q2-202336803.html">missed Q2 estimates</a>.</li>



<li>Dutch Bros (NYSE:<a href="https://investorplace.com/stock-quotes/bros-stock-quote/">BROS</a>) stock is dropping more than 21% <a href="https://seekingalpha.com/news/4136791-coffee-jolt-dutch-bros-gets-crushed-after-just-a-slight-miss-with-revenue-guidance">after missing estimates</a>.</li>



<li>Know Labs (NYSEMKT:<a href="https://investorplace.com/stock-quotes/knw-stock-quote/">KNW</a>) shares are decreasing over 21% after <a href="https://www.nasdaq.com/press-release/know-labs-inc-announces-pricing-3445-million-public-offering-2024-08-07">pricing a public offering</a>.</li>



<li>Vertex Energy (NASDAQ:<a href="https://investorplace.com/stock-quotes/vtnr-stock-quote/">VTNR</a>) stock is falling more than 20% <a href="https://www.stocktitan.net/news/VTNR/vertex-energy-announces-second-quarter-2024-enonsrelirjb.html">with its Q2 earnings report</a>,</li>



<li>Fastly (NYSE:<a href="https://investorplace.com/stock-quotes/fsly-stock-quote/">FSLY</a>) shares close out our pre-market stock movers down over 19% <a href="https://www.investing.com/news/stock-market-news/fastly-shares-plunge-19-as-guidance-disappoints-despite-solid-q2-93CH-3560546">on a lackluster guidance</a>.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/08/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-thursday-aug-8th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

AstraZeneca licensing deal boosts Conduit Pharma

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Conduit Pharmaceuticals&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/cdt-stock-quote/">CDT</a>) stock is rocketing higher on Thursday after the clinical-stage specialty biopharmaceutical company announced <a href="https://www.nasdaq.com/press-release/conduit-pharmaceuticals-enters-exclusive-license-agreement-astrazeneca-multiple">an exclusive license agreement</a> with AstraZeneca&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/azn-stock-quote/">AZN</a>).



This has Conduit Pharmaceuticals obtaining exclusive rights for three product candidates in development at AstraZeneca. That includes HK-4 glucokinase activators AZD1656 and AZD5658, as well as myeloperoxidase inhibitor AZD5904.



Development progress includes AZD1656 and AZD5904 already completing Phase 1 clinical trials. Conduit Pharmaceuticals also notes that it intends to launch Phase 2 clinical trials for AZD1656 and AZD5658 this year. It intends to test their effectiveness as autoimmune disorder treatments.



Conduit Pharmaceuticals CEO Dr.&nbsp;David Tapolczay said the following about the deal.




&ldquo;The potential of these assets to become important first-in-class medicines for patients is promising. Given the data from AstraZeneca&rsquo;s clinical trials, we believe there is a strong rationale to initiate Phase II studies in multiple indications to progress to commercialization of these assets.&rdquo;




<h2>CDT Stock Jumps on AZN Agreement</h2>



News of this license agreement brings with it heavy trading of CDT stock. That has more than 39 million shares of AZN trading hands as of this writing. This is well above its daily average trading volume of about 3 million shares.



CDT stock is up 123.2% as of Thursday morning.



Investors will want to stick around for even more of the most recent stock market news today.



We have all of the hottest market happenings worth reading about on Thursday. That includes the biggest pre-market stock movers this morning and more. All of that info is ready to go at the links below!



<h2>More Thursday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/08/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-thursday-aug-8th/">Today&rsquo;s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on&nbsp;Thursday</a></li>



<li><a href="https://investorplace.com/2024/08/ftnt-stock-alert-why-investors-are-piling-into-fortinet-today/">FTNT Stock Alert: Why Investors Are Piling Into Fortinet Today</a></li>



<li><a href="https://investorplace.com/2024/08/why-is-lyft-stock-down-despite-surprise-q2-profits/">Why Is LYFT Stock Down Despite Surprise Q2 Profits?</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/08/why-is-conduit-pharmaceuticals-cdt-stock-up-123-today/">Why Is Conduit Pharmaceuticals (CDT) Stock Up 123% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Conduit Pharmaceuticals (CDT) Stock Up 123% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Conduit Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/cdt-stock-quote/">CDT</a>) just reported results for the second quarter of 2024.<ul><li>Conduit Pharmaceuticals reported earnings per share of -7 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/cdt-stock-earnings-conduit-pharmaceuticals-for-q2-of-2024/">CDT Stock Earnings: Conduit Pharmaceuticals Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

CDT Stock Earnings: Conduit Pharmaceuticals Reported Results for Q2 2024

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are a hot topic on Wednesday and we have all of the biggest stories traders need to know about this morning!



Moving stocks this morning are earnings reports, a stock offering, a reverse stock split and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Digital Ally (NASDAQ:<a href="https://investorplace.com/stock-quotes/dgly-stock-quote/">DGLY</a>) stock is rocketing more than 107% alongside heavy pre-market trading.</li>



<li>Viracta Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/virx-stock-quote/">VIRX</a>) shares are soaring over 53% with the <a href="https://www.nasdaq.com/press-release/viracta-therapeutics-reports-second-quarter-2024-financial-results-and-provides">release of its Q2 earnings report</a>.</li>



<li>Conduit Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/cdt-stock-quote/">CDT</a>) stock is surging more than 42% on <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318518494&amp;type=PDF&amp;symbol=CDT&amp;cdn=197541151657f71d6ed19abcc1e0e48e&amp;companyName=Conduit+Pharmaceuticals+Inc.&amp;formType=3&amp;formDescription=Initial+statement+of+beneficial+ownership+of+securities&amp;dateFiled=2024-08-13">an investment update</a>.</li>



<li>Nuburu (NYSEMKT:<a href="https://investorplace.com/stock-quotes/buru-stock-quote/">BURU</a>) shares are rising over 26% despite a lack of news this morning.</li>



<li>Jianzhi Education Technology (NASDAQ:<a href="https://investorplace.com/stock-quotes/jz-stock-quote/">JZ</a>) stock is gaining close to 19% even with a <a href="https://www.nasdaq.com/press-release/jianzhi-education-technology-group-company-limited-receives-nasdaq-notification-0">recent delisting notice</a>.</li>



<li>Edible Garden (NASDAQ:<a href="https://investorplace.com/stock-quotes/edbl-stock-quote/">EDBL</a>) shares are increasing more than 18% on <a href="https://www.nasdaq.com/press-release/edible-garden-reports-157-increase-gross-profit-fueled-year-over-year-growth-61-cut">strong Q2 earnings</a>.</li>



<li>Ucloudlink (NASDAQ:<a href="https://investorplace.com/stock-quotes/ucl-stock-quote/">UCL</a>) stock is heading over 16% higher with its <a href="https://www.nasdaq.com/press-release/ucloudlink-group-inc-announces-unaudited-second-quarter-2024-financial-results-2024">most recent earnings report</a>.</li>



<li>Vertex Energy (NASDAQ:<a href="https://investorplace.com/stock-quotes/vtnr-stock-quote/">VTNR</a>) shares are jumping 16% with strong early morning trading.</li>



<li>Serve Robotics (NASDAQ:<a href="https://investorplace.com/stock-quotes/serv-stock-quote/">SERV</a>) stock is climbing more than 15% with its <a href="https://www.stocktitan.net/news/SERV/serve-robotics-announces-second-quarter-2024-wqwtqr037uv4.html">Q2 earnings report</a>.</li>



<li>Kamada (NASDAQ:<a href="https://investorplace.com/stock-quotes/kmda-stock-quote/">KMDA</a>) shares are up over 15% after posting <a href="https://www.nasdaq.com/press-release/kamada-reports-strong-second-quarter-and-first-half-2024-financial-results-year-over">positive Q2 earnings results</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>TC BioPharm (NASDAQ:<a href="https://investorplace.com/stock-quotes/tcbp-stock-quote/">TCBP</a>) stock is crashing more than 42% after <a href="https://www.nasdaq.com/press-release/tc-biopharm-announces-pricing-20-registered-direct-offering-2024-08-13">pricing a registered direct offering</a>.</li>



<li>Surgepays (NASDAQ:<a href="https://investorplace.com/stock-quotes/surg-stock-quote/">SURG</a>) shares are plummeting over 26% after <a href="https://www.prnewswire.com/news-releases/surgepays-announces-second-quarter-2024-financial-results-302221503.html">reporting a Q2 loss</a>.</li>



<li>Arcadia Biosciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/rkda-stock-quote/">RKDA</a>) stock is diving more than 16% after <a href="https://markets.businessinsider.com/news/stocks/rkda-stock-earnings-arcadia-biosciences-for-q2-of-2024-1033684150">missing Q2 EPS estimates</a>.</li>



<li>Ouster (NYSE:<a href="https://investorplace.com/stock-quotes/oust-stock-quote/">OUST</a>) shares are taking an over 16% beating on <a href="https://www.businesswire.com/news/home/20240813944318/en/Ouster-Reports-Strong-Revenue-and-Margins-for-Second-Quarter-2024">mixed Q2 earnings</a>.</li>



<li>QuickLogic (NASDAQ:<a href="https://investorplace.com/stock-quotes/quik-stock-quote/">QUIK</a>) stock is tumbling more than 16% with its <a href="https://www.prnewswire.com/news-releases/quicklogic-reports-41-year-over-year-revenue-growth-for-second-quarter-fiscal-2024-302221555.html">latest earnings release</a>.</li>



<li>Brinker International (NYSE:<a href="https://investorplace.com/stock-quotes/eat-stock-quote/">EAT</a>) shares are sliding over 16% after <a href="https://www.investing.com/news/stock-market-news/brinker-international-stock-tumbles-13-on-q4-earnings-miss-93CH-3570960">posting an earnings miss</a>.</li>



<li>Portage Biotech (NASDAQ:<a href="https://investorplace.com/stock-quotes/prtg-stock-quote/">PRTG</a>) stock is falling more than 15% after <a href="https://www.stocktitan.net/news/PRTG/portage-biotech-announces-1-for-20-reverse-stock-sficaewojjpr.html">announcing a reverse stock split</a>.</li>



<li>Global E Online (NASDAQ:<a href="https://investorplace.com/stock-quotes/glbe-stock-quote/">GLBE</a>) shares are decreasing over 14% with its <a href="https://www.stocktitan.net/news/GLBE/global-e-reports-second-quarter-2024-1dq5hcfetvn1.html">Q2 earnings report</a>.</li>



<li>Bionomics (NASDAQ:<a href="https://investorplace.com/stock-quotes/bnox-stock-quote/">BNOX</a>) stock is dropping more than 14% without any clear news this morning.</li>



<li>WISeKey (NASDAQ:<a href="https://investorplace.com/stock-quotes/wkey-stock-quote/">WKEY</a>) shares close out our pre-market stock movers down nearly 14% on a <a href="https://www.nasdaq.com/press-release/sealcoin-secures-50-million-investment-commitment-gem-digital-limited-through-0">new investment</a> <a href="https://www.nasdaq.com/press-release/wisekey-partners-venafi-post-quantum-encryption-services-2024-08-14">and partnership</a>.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/08/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-aug-14th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Conduit Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/cdt-stock-quote/">CDT</a>) stock is up on Wednesday following a shareholder update concerning a major investor in the company.



New filings with the Securities and Exchange Commission (SEC) reveal that Nirland Limited <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318518480&amp;type=PDF&amp;symbol=CDT&amp;cdn=ab0223c3ed6ed1bb801100f67e0b2323&amp;companyName=Conduit+Pharmaceuticals+Inc.&amp;formType=SC+13G%2FA&amp;formDescription=%5BAmend%5D+Statement+of+acquisition+of+beneficial+ownership+by+individuals&amp;dateFiled=2024-08-13">holds a 14.8% stake in CDT stock</a>. This comes from the 12.5 million shares off CDT that the company owns, as well as warrants for another 2 million shares.



Nirland Limited&rsquo;s stake in Conduit Pharmaceuticals is based on the company&rsquo;s outstanding shares of CDT stock. That was sitting at 98,004,699 shares at the time of this writing.



Nirland Limited&rsquo;s stake in Conduit Pharmaceuticals comes from a Senior Secured Promissory Note issued earlier this month. This was part of Conduit Pharmaceuticals&rsquo; merger agreement with Murphy Canyon Acquisition Corp.



<h2>CDT Stock Movement on Wednesday</h2>



Following this news, shares of CDT stock are seeing heavy trading today. This has more than 72 million units changing hands as of this writing. That&rsquo;s a massive increase compared to the company&rsquo;s daily average trading volume of about 10 million shares.



CDT stock is up 11.7% as of Wednesday morning. Even so, the clinical-stage specialty biopharmaceutical company&rsquo;s shares are still down 96.7% since the start of the year.



Investors will want to stick around for even more of the most recent stock market stories on Wednesday!



We have all of the hottest stock market news ready to go today! Among that is what has shares of Intuitive Machines&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/lunr-stock-quote/">LUNR</a>), Nuburu&nbsp;(NYSEMKT:<a href="https://investorplace.com/stock-quotes/buru-stock-quote/">BURU</a>) and Clover Health&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/clov-stock-quote/">CLOV</a>) stock on the move today. You can catch up on all of this at the links below!



<h2>More Stock Market News for Wednesday</h2>



<ul><li><a href="https://investorplace.com/2024/08/trade-of-the-day-explore-the-final-frontier-with-intuitive-machines-lunr-stock/">Trade of the Day: Explore the Final Frontier with Intuitive Machines (LUNR) Stock</a></li>



<li><a href="https://investorplace.com/2024/08/why-is-nuburu-buru-stock-up-47-today/">Why Is Nuburu (BURU) Stock Up 47% Today?</a></li>



<li><a href="https://investorplace.com/2024/08/clov-stock-alert-what-to-know-about-clover-healths-big-insider-buy/">CLOV Stock Alert: What to Know About Clover Health&rsquo;s Big Insider Buy</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/08/why-is-conduit-pharmaceuticals-cdt-stock-up-12-today/">Why Is Conduit Pharmaceuticals (CDT) Stock Up 12% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Conduit Pharmaceuticals (CDT) Stock Up 12% Today?

06:14 EDT Conduit Pharmaceuticals (CDT) files $100M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-mo...

Conduit Pharmaceuticals files $100M mixed securities shelf

Conduit Pharmaceuticals ( ($CDT) ) has issued an update. Conduit Pharmaceuticals Inc. recently entered into financial agreements to secure funding,...

Conduit Pharmaceuticals Secures Funding and Modifies Debt Agreements

Conduit Pharmaceuticals announces debt restructuring and additional notes

AMIX

APPS

ASPN

BMBL

BNOX

BROS

BURU

CDLX

CMPO

COEP

DGLY

EDBL

EFSH

FROG

FSLY

GLBE

GNLN

GRNQ

HROW

KMDA

KVYO

LUXH

OUST

PRTG

QUIK

RKDA

SERV

SILO

SURG

TCBP

VIRX

VTNR

WENA

WKEY

Press Releases

Conduit Pharmaceuticals Announces Opening of Prime Laboratory Space in Europe's Leading Life Sciences Hub

Management

Conduit Pharmaceuticals Appoints Dr. Joanne Holland as Chief Scientific Officer

General

A Presidio Property Trust Major Investment To Be Part of Russell 2000®

Conduit Pharmaceuticals to Join Russell 3000® Index

Health Care

Legal

Conduit Pharmaceuticals Receives Patent Approval For Its Lead Asset Targeting Autoimmune Diseases

Conduit Pharmaceuticals Enters into Exclusive License Agreement with AstraZeneca for Multiple Assets to Advance Potential First-in-Class Treatments

Conduit Pharmaceuticals Selects Initial Indications for Lead Clinical Candidate Targeting Autoimmune Disorders

Conduit Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Comments

Conduit Pharmaceuticals

Conduit Pharmaceuticals (CDT) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL